Aims: Vascular invasion is a prognostic marker for many cancers, including endometrial carcinoma. Immunohistochemistry using D2-40 and CD31 antibodies makes it possible to differentiate between lymphatic vascular invasion (LVI) and blood vessel invasion (BVI). The aim was to examine lymphatic and blood vessel invasion separately and their associations with clinicopathological characteristics and prognosis. Methods and results: Immunohistochemistry was performed on a retrospective population-based series of endometrial carcinoma. Altogether, 31% of the 276 tumours showed lymphatic involvement, whereas 18% showed blood vessel invasion. LVI and BVI were associated with histopathological variables such as histological grade and tumour growth pattern. Patients without vascular invasion had the best prognosis and those with BVI (with or without LVI) had the worst outcome, whereas patients with LVI had an intermediate survival on univariate analysis. Multivariate models indicated that both LVI and especially BVI had independent prognostic importance. Among endometrioid carcinomas, BVI was still significant. Conclusions: Our findings support the biological importance of vascular spread through the haematogenic and lymphatic routes in endometrial cancer. The significant correlation found with clinical phenotype indicates that these markers may be relevant for patient management.
Introduction
Endometrial cancer is the fourth most frequent cancer and the most common malignant tumour in the female genital tract among women in the Western world. 1 The majority of endometrial cancers are diagnosed at an early stage and have a good prognosis, although a smaller subgroup is more aggressive. 2 Prognostic markers are important for optimal treatment and follow-up of these patients.
The presence of vascular invasion (VI) is a prognostic factor in many cancers such as endometrial, breast, prostatic, thyroid, urinary bladder carcinoma and cutaneous melanoma, [3] [4] [5] [6] [7] [8] [9] and vascular involvement is considered an early step in the metastatic process. Previously, studies of endometrial cancer have shown that the presence of tumour cells within vascular spaces is a strong predictor of nodal metastasis, recurrence and cancer-specific death. [10] [11] [12] However, most of these tissue-based studies did not discriminate between blood vessels and lymphatic vasculature, mostly due to the lack of reliable lymphatic markers.
In malignant tumours, blood vessels often show an abnormal structure. 13 Less mature vessels with reduced coverage of perivascular cells positive for smooth muscle actin have been associated with increased VI and reduced survival. 14 During blood vessel invasion (BVI), the basement membrane is degraded so that tumour cells might enter the lumen. Lymphatic vascular invasion (LVI) is thought to be more easily executed, since lymphatics have less stable walls with more open inter-endothelial junctions. 15 Subsequently, tumour cells are transported to secondary organs, where extravasation occurs. If the microenvironment is permissive in these target organs, tumour cells can expand to form growing metastases.
Malignant tumours appear to have different preferences regarding lymphatic or haematogenous spread, a feature that may be important for further disease progress. The aim of this study was to examine the occurrence and prognostic significance of BVI and LVI in a population-based series of endometrial carcinoma with long follow-up.
Material and methods

patient series
All patients diagnosed with endometrial carcinoma in Hordaland County (Norway) during the period 1981-1990 were studied. This endometrial cancer series and the variables histological type, histological grade, solid growth, growth pattern, necrosis, mitoses and International Federation of Gynaecology and Obstetrics (FIGO) stage have been described previously. 7, 16 The variables tumour-infiltrating lymphocytes (TIL) and perivascular lymphocytic infiltration (PLI) were examined on haematoxylin and eosin (H&E)-stained sections. The presence of TIL was recorded as absent, non-brisk or brisk. 17 PLI was registered as present if mononuclear cells were found around a vascular space in the myometrium and absent if no such feature was seen. 18, 19 The median age of the patients at primary treatment was 65.2 years (range 33.5-92.3 years).
H&E-stained sections from each case have previously been classified as either VI+ or VI). 7 VI was considered positive when groups of tumour cells were seen within spaces lined by flattened cells, 20 and vascular involvement was predominantly found at the tumour front. Further, one representative block from each case was selected for immunohistochemistry. For those tumours previously scored as VI), the block with deepest tumour invasion was used. Of the 286 tumours that had previously been examined by H&E staining for VI, 7 276 cases (96.5%) were available for the present study; in two of the 102 positive cases based on H&E slides, a different tumour block was examined by immunohistochemistry.
The follow-up data were collected from the medical records and correspondence with the primary physicians, with respect to disease recurrence and deaths. The median follow-up period for the survivors was 9 years (range 5-15 years). None of the patients was lost due to insufficient follow-up information. Among the 117 patients who died during the follow-up period, 70 died from endometrial carcinoma and 47 died from other causes. The follow-up data were cross-checked with information from the Cancer Registry of Norway, which is matched against the Register of Deaths of Statistics Norway. 7, 16 immunohistochemistry The immunohistochemical study was done on 5-lm sections of paraffin-embedded tumour tissue using the D2-40 antibody (M3619; Dako, Glostrup, Denmark) for lymphatic vessel staining, and the CD31 antibody clone JC70A (M0823; Dako) for blood vessel staining. Briefly, sections were dewaxed with xylene and rehydrated in ethanol before microwave antigen retrieval. For D2-40, sections were boiled in TE buffer pH 9, 10 min at 750 W followed by 15 min at 350 W and then incubated with D2-40 antibody diluted 1:100 for 30 min at room temperature. For CD31, sections were boiled in target retrieval solution pH 6.0 (Dako), 10 min at 750 W followed by 20 min at 350 W and then incubated with the monoclonal antibody CD31 diluted 1:25 for 60 min at room temperature. Staining was carried out using the mouse EnVision Kit (Dako) with diaminobenzidine peroxidase (Dako) as substrate. Finally, the sections were counterstained with Dako REAL haematoxylin for 1 min (Dako).
lvi and bvi classification D2-40 has previously been reported as a sensitive and specific lymphatic marker. 21, 22 We here found positive and distinct expression in vessels not containing red blood cells. CD31 was primarily used for blood vessel identification, but this marker is not completely specific and might show weak immunoreactivity also in lymphatic endothelium. 23 LVI was therefore recorded when a vessel showed positivity for D2-40, whereas BVI was reported when the vessel was positive for CD31 and negative for D2-40. Some tumours showed both LVI and BVI. All slides were examined by M.M. and I.S., and both observers were blinded for clinicopathological information and follow-up. In cases with uncertainty, two pathologists (I.S. and L.A.A.) examined the slides and reached consensus. was used as the starting point. VI, together with standard clinicopathological variables, was further analysed by log-log plot to determine how these variables could be incorporated in the Cox' proportional hazards regression model (L ratio significance test). Tests for interactions were carried out for the variables that were significantly related to survival in the Cox' regression analysis. A result was considered significant when P < 0.05.
Results
Based on H&E slides, vascular invasion (VI+) was found in 36% of cases and was significantly associated with histopathological variables such as histological grade, tumour growth pattern and solid growth (Table 1) . By immunohistochemistry, 40% of the cases were positive, and results by H&E and immunohistochemistry were significantly correlated (Pearson's v 2 , P < 0.001). Vascular invasion status by immunohistochemistry was further divided into four different subgroups by combinations of D2-40 and CD31 staining (Figure 1 ). Of the 276 tumours investigated, 166 (60%) did not show any VI (VI)), 60 (22%) showed LVI only, 26 (9%) BVI only and 24 (9%) showed both BVI and LVI (Table 2) . Of the 176 cases classified on H&E sections to be VI), immunohistochemistry classified 16 to have LVI, four to have BVI and one to have BVI + LVI, indicating that 12% of cases previously reported to be negative showed VI by immunohistochemistry. Of the 102 cases classified as VI+ in H&E sections, immunohistochemistry could not confirm this in 13 cases (13%) ( Table 1) . When the analysis was restricted to cases with matching tumour blocks for positive cases (n = 100; immunohistochemistry performed on positive H&E blocks), practically identical results were found (not shown). Table 3 shows the associations between clinicopathological variables and the four subgroups determined. Overall, VI by immunohistochemistry was significantly associated with histological grade, diffusely infiltrative growth pattern, solid tumour growth, presence of necrosis, PLI and TIL. Considering differences between BVI and LVI in separate analyses, BVI appeared to be especially associated with a diffusely invasive growth pattern (P = 0.001), whereas lymphatic involvement was predominantly associated with perivascular (P < 0.001) and tumour-infiltrating lymphocytes (P = 0.013). survival analysis VI detected in H&E-stained sections is a strong prognostic factor (Figure 2A) . When separating the subgroups with BVI and LVI by immunohistochemistry, cases with LVI only defined a patient subgroup with intermediate prognosis with respect to patient survival, whereas those with BVI with and without LVI had the worst prognosis ( Figure 2B ). When looking at recurrence-free survival, a similar pattern was found ( Figure 2C,D) . Looking at specific end-points for recurrent disease, BVI only was related to local recurrences, whereas both BVI and LVI were associated with recurrences (metastases) in distant organs, BVI more so than LVI (data not shown).
In later survival analyses, the two subgroups with BVI (BVI ± LVI) were fused due to similar survival curves. The 5-year survival rate was 86% for negative cases, 69% for LVI cases, and 51% and 54% for BVI and BVI + LVI cases, respectively ( Table 4 ). The prognostic impact of the other clinicopathological variables is listed in Table 4 .
On multivariate survival analysis, the standard clinicopathological variables such as histological type, histological grade and FIGO stage were included together with VI by immunohistochemistry in three groups. LVI and BVI ± LVI both appeared to be independent prognostic markers for survival, with hazard ratios (HR) of 1.8 and 3.2 for LVI and BVI ± LVI, respectively (Table 5) , although LVI was weaker than BVI. Histological type (HR 2.2, P = 0.010), histological grade (HR 2.1, P = 0.010) and FIGO stage (HR 7.9, P < 0.001) were all independent prognostic factors ( Table 5) . Vascular classification by immunohistochemistry was also found to be an independent prognostic marker of recurrence-free survival adjusted for the same standard clinicopathological variables, with HR of 4.5 [95% confidence interval (CI) 2.0, 10.5, P < 0.001] and 8.7 (95% CI 3.9, 19.5, P < 0.001) for LVI and BVI ± LVI, respectively (Table 6) .
A separate multivariate survival analysis of the endometrioid subgroup showed that BVI ± LVI was still a highly significant predictor of prognosis (HR 3.7, P < 0.001), in addition to histological grade (HR 2.1, P = 0.011) and FIGO stage (HR 10.0, P < 0.001), in contrast to LVI (P = 0.37). As regards recurrence-free survival, LVI (HR 3.8, P = 0.013), BVI ± LVI (HR 14.9, P < 0.001) and FIGO stage (HR 4.3, P < 0.001) were significant factors in multivariate analysis.
Discussion
VI is considered an important prognostic factor in endometrial cancer 7 and several other malignant tumours. Previous studies in this field have not distinguished between BVI and LVI. However, it has been considered that probably a majority of cases with VI on H&E-stained slides represent LVI. In our present study, the aim was to separate BVI and LVI by immunohistochemistry. We found that 31% of the cases showed lymphatic involvement, whereas 18% showed BVI. Altogether, 40% of tumours had some sort of VI, and 9% showed both LVI and BVI. On multivariate analysis, both lymphatic involvement and especially BVI demonstrated independent prognostic importance, the latter being the strongest factor, indicating that both of these characteristics are biologically important for the clinical progress of endometrial cancer.
In previous studies, it has not been possible to separate lymphatic and blood vessel involvement. However, several studies have examined the presence of lymph-vascular space invasion (LVSI) in endometrial cancer, including both BVI and LVI. 7, 10, 11, 24, 25 The frequency of LVSI varies from 14 to 35%, depending on the criteria and also on patient materials used. LVSI correlates to an aggressive phenotype and appears to be a significant prognostic factor in endometrial cancer. 24 To our knowledge, our study is the first to present data separating LVI and BVI in these tumours.
Comparing the results from H&E and immunohistochemical sections, 12% of negative cases on H&E were positive by immunohistochemistry. Similarly, 13% of cases positive on H&E slides could not be confirmed by immunohistochemistry. Several factors might contribute to explain this. First, different tissue blocks were used in a few cases, and deeper sections were cut to perform immunohistochemistry. In some cases, artefacts based on tissue shrinkage might have been misinterpreted to represent vascular spaces. Obviously, immunohistochemical markers of blood and lymphatic endothelium increase the sensitivity and specificity of what should be considered a real vascular space. Also, when VI status on H&E slides was determined, 7 all available sections were examined per case, whereas only one master-block was examined by immunohistochemistry in the present study.
We have shown that LVI was associated with several histopathological features such as a diffusely invasive growth pattern, more solid tumour growth, tumour necrosis, PLI and TIL. Of interest, the presence of PLI appeared to be predominantly associated with lymphatic involvement. Even though LVI was found to be significantly associated with many aggressive features, blood vessel involvement indicated an even poorer prognosis. This concurs with the general view that BVI is associated with more widespread metastases to distant organs and thus poorer prognosis. In our study, LVI defined a group of patients with intermediate prognosis between patients with no vascular involvement and those with BVI. When BVI was present, lymphatic involvement had no additional prognostic impact, indicating that BVI is biologically dominant.
We found significant differences in the occurrence of BVI and LVI in endometrial cancer. Studies of breast, colorectal and cervical cancers have reported BVI in 1-38% and LVI in 31-70% of cases. The finding that LVI is more frequent than BVI 4, [26] [27] [28] is in accordance with the present series. A study of 95 breast cancer patients showed that 70% and 38% of the patients had LVI and BVI, respectively. Both markers showed an association with features of aggressive tumours. 26 Another study of 177 primary invasive breast tumours, showing 31% LVI but only 1% BVI, is thus strikingly different from other studies. VI was associated with poorer prognosis and adverse clinicopathological characteristics. 4 A study of 419 colorectal carcinoma patients showed 6% BVI, 19% LVI and 35% BVI + LVI. LVI was associated with lymph node metastasis and BVI was related to distant recurrence and patient survival. 28 In 239 cervical cancers, LVI was detected in 56% and BVI in 21%. LVI was related to lymph node metastasis, and BVI was a significant prognostic factor independent of both LVI and lymph node metastasis. However, this study was based on H&E slides only. 27 In conclusion, our study has indicated that lymphatic involvement is more frequent than BVI (31% versus 18%), but blood vessel involvement is a stronger prognostic factor among endometrial carcinomas.
